Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elan Sets Up For Sale With Neotope Biosciences Spinout

This article was originally published in The Pink Sheet Daily

Executive Summary

Elan’s sole near-term growth prospect is Tysabri after the Irish drug maker spins out its discovery research unit Neotope Biosciences with $120 million to $130 million in start-up capital.

You may also be interested in...



Elan’s Martin Aims To Set The Record Straight About Recent Buying Spree

Changes at the Irish company have sparked a swath of media speculation and analyst interest. Elan CEO Kelly Martin used a recent fireside chat in New York to paint a clearer picture of what is going on at the company and the rationale behind its recently proposed M&A.

Elan Tries To Transform With Three New Deals; Wall Street Still Skeptical

In its continuing effort to spend its way into becoming a diversified pharma, Elan announced a new trio of deals. Some liken its geographically diverse, specialty pharma strategy to that of highly successful Valeant, but Wall Street remains unsure that Elan can execute. Hostile bidder Royalty Pharma took the opportunity to further tempt shareholders by raising its offer.

Deals Of The Week: Mylan/Agila, UCB/Biotie, Jazz/Concert…

Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS074502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel